Dallas, Texas – September 30, 2023 — LEXAGENE LIFE SCIENCES —
A NEW ERA OF LEADERSHIP AND INNOVATION IN BIOPHARMACEUTICAL CONTAMINATION TESTING
“Our solution will help secure the safe and fast availability of medications needed by humans, our pets and food production animals.”
LexaGene Life Sciences, LLC (“LLS”) was formed in 2023 to acquire and further develop the technology assets of a predecessor company, LexaGene Holdings, Inc. (“Holdings”). Holdings was founded in 2016 by Dr. Jack Regan, a specialist in the field of rapid microbial detection, carving out a niche in underserved markets with the innovative MiQLab® System.
Holdings initially focused on companion animal veterinary bacterial diagnostics, however in June 2023, a significant shift occurred when the largest equity holder of Holdings acquired the company’s assets and formed LLS. This strategic acquisition marks a new beginning for the MiQLab® System technology – an invigorated focus and leadership to expand its horizons to address microbial contaminants in human and veterinary biopharmaceutical manufacturing.
New Management Combined With Retained Expertise: LexaGene Life Sciences has made a pivotal decision to retain Dr. Jack Regan as Chief Technology Officer. This move ensures continuity in the company’s scientific vision and expertise. Complementing Dr. Regan’s technical expertise, the new management team brings a wealth of experience and fresh strategic perspectives, particularly targeting the biopharmaceutical manufacturing market.
The company has hired Tom Forte as the new Chief Executive Officer and President to lead the company’s efforts and Tom begins his tenure January 1, 2024. Tom brings extensive experience in the biopharmaceutical and veterinary diagnostic industries. Most recently he served as President of Covetrus North America, a >$2.7B business, with a mission of ensuring their portfolio of technology, service, and product solutions helped drive better outcomes. His prior roles include Chief Commercial Officer at Covetrus North America and extensive sales, marketing, and other commercial leadership positions at Pfizer Inc, Pfizer Animal Health (Zoetis), and Johnson & Johnson.
Expanding Market Horizons: The biopharmaceutical sector (both human and veterinary), with their stringent safety standards and need for rapid, accurate microbial contamination testing, presents a ripe opportunity for LexaGene’s MiQLab® 2nd Generation System. This fully automated, sample-to-answer PCR system represents a leap forward in detecting and characterizing microbes, offering unparalleled efficiency and precision.
The significance of contamination risk and dissatisfaction with current market solutions has been validated by (1) two leading biopharma manufacturers that purchased our 1st generation MiQLab® systems to conduct feasibility studies, (2) additional market research, and (3) direct discussions with other large biopharma companies’ manufacturing & quality leadership team.
Beyond Biopharmaceuticals: While the primary focus is the biopharmaceutical manufacturing industry, LexaGene Life Sciences is poised to tap into other lucrative markets. The versatility of the MiQLab® System positions the company to potentially expand into food safety testing, water safety testing, and veterinary diagnostics. Each of these markets shares a common need for innovative, reliable testing solutions, which LexaGene is uniquely equipped to provide.
A Vision for the Future: The formation of LexaGene Life Sciences is more than a corporate restructuring; it’s a strategic alignment for future growth. With a robust product in the MiQLab® System and a dynamic new management team, the company is well-positioned to significantly alter the landscape of microbial PCR testing across multiple industries.
For potential investors, this transition represents an exciting opportunity. LexaGene Life Sciences is not just carrying forward a legacy of innovation; it is expanding and enhancing it. The company’s focus on meeting unmet needs in critical sectors, combined with its technological expertise and refreshed leadership, makes it a compelling prospect for those looking to invest in cutting-edge life science technology, as there is an existing $20 billion market opportunity with substantial room for growth driven by new biopharma products, an evolving manufacturing process, and unmet needs in mitigating the high-risk of contamination.
As LexaGene Life Sciences steps into this new era, it stands at the forefront of PCR testing innovation, ready to make significant impacts in biopharmaceuticals and beyond. The journey ahead is promising, and the company invites investors to be a part of this transformative venture.
For more information about LexaGene and the MiQLab System, please visit www.lexagenelifesciences.com
LexaGene Life Sciences, LLC
LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.